Adoptive chemoimmunotherapy using Ex vivo activated memory T‐cells and cyclophosphamide: Tumor lysis syndrome of a metastatic soft tissue sarcoma
- 1 September 1993
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 44 (1), 42-47
- https://doi.org/10.1002/ajh.2830440109
Abstract
Adoptively transferred immune cells in combination with chemotherapeutic agents form the basis for adoptive chemoimmunotherapy (ACIT) of neoplastic disease. Autolympho-cytes (ALT-cells) are ex vivo activated peripheral blood lymphocytes (PBL) from tumor-bearing hosts (TBH) that consist primarily of tumor-specific CD45RO+ (memory) T-cells. These ALT-cells combined with cimetidine (CIM) as autolymphocyte therapy (ALT), have previously been demonstrated to be a safe and active form of outpatient adoptive immunotherapy (AIT) in human TBH with metastatic renal cell cancer (RCC). We have previously described an effective ACIT protocol using ALT and cyclophosphamide (CY) for patients with relapsed and refractory non-RCC solid tumors. We now report a case of a patient with a metastatic gastric leiomyosarcoma to the liver, who developed a clinical picture consistent with a tumor-lysis syndrome (TLS), following salvage therapy for his tumor with ACIT using ALT and CY. TLS is a well-known complication resulting from the treatment of rapidly proliferating hematopoietic tumors such as Burkitt's lymphoma and acute lymphocytic leukemia. TLS has also been rarely described in chronic lymphocytic leukemia, as well as certain solid tumors such as breast cancer, small cell lung cancer, and medulloblastoma. However, there have been no previous reports of TLS occurring either secondary to immunotherapy or in sarcomas. The nature of these unusual findings is discussed.Keywords
This publication has 34 references indexed in Scilit:
- Adoptive Chemoimmunotherapy for the Treatment of Relapsed and Refractory Solid Tumors Using Ex Vivo Activated Memory T Cells (Autolymphocyte Therapy) and CyclophosphamideJournal of Immunotherapy, 1993
- Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary reportCancer, 1991
- Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinomaThe Lancet, 1990
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Potentiation of adoptive immunotherapy by cis‐diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burdenInternational Journal of Cancer, 1988
- T-Cell Tumor Elimination as a Result of T-Cell Receptor-Mediated ActivationScience, 1987
- Acute tumor lysis syndrome in prolymphocytic leukemiaArchives of Internal Medicine, 1987
- Hyperphosphatemia, hypocalcemia, and transient renal failure. Results of cytotoxic treatment of acute lymphoblastic leukemiaPublished by American Medical Association (AMA) ,1978
- Metabolic complications of aggressive therapy of chronic lymphocytic leukemiaThe American Journal of the Medical Sciences, 1974